Bilal Butt, MD

Assistant Professor of Clinical Neurology, Specialty in NeuroCritical Care and Stroke
Neurology

    About me

    Dr. Bilal Butt is an Assistant Professor in the Department of Neurology at Southern Illinois University School of Medicine. He is a neurologist who specializes in Neuro Critical Care and Stroke.  Dr. Butt is Clerkship Director for Neurology.

    Dr. Butt earned his medical degree at Ross University School of Medicine in West Indies. He completed his internal medicine residency at Baylor College of Medicine in Houston, Texas and then his Neurology residency at Wayne State University/DMC in Detroit, Michigan. Following this he completed a fellowship in Neurocritical Care at Baylor College of Medicine in Houston, Texas.

    Dr. Butt is certified by the American Board of Psychiatry and Neurology (ABPN) and is board eligible for certification in Neuro Critical Care. He is a member of American Academy of Neurology and Neuro Critical Care Society. His research interests include critical care and subarachnoid hemorrhage.

    Gender

    Male

    Languages spoken

    Urdu

    Education & training

    Positions
    Neurologist
    Board Certifications
    Neurology
    Medical School
    Ross University School of Medicine, Dominica, West Indies
    Undergraduate Degree
    York University, Toronto, ON - BS (Honors), Biological Sciences
    Residency
    Baylor College of Medicine, Houston - Internal Medicine
    Wayne State University/DMC, Detroit - Neurology
    Fellowship
    Baylor College of Medicine, Houston - NeuroCritical Care

    Clinical trials

    Trial
    Neurology

    Portola: A Randomized Clinical Trial of Andexanet Alfa in Acute Intracranial Hemorrhage in Patients Receiving an Oral Factor XA Inhibitor

    Active not recruiting

    ANNEXa-1 (18-513): This is a randomized, multicenter clinical trial designed to determine the efficacy and safety of andexanet compared to usual care in patients presenting with acute intracerebral hemorrhage within 6 hours of symptom onset (from the baseline scan) and within 15 hours of taking an oral FXa inhibitor (from randomization). The study will use a prospective, randomized, open-label design, as it is unfeasible to blind the Investigator to the treatment assignment given the many potential therapeutic options available under usual care treatment.